Cellectis Stock Price, News & Analysis (NASDAQ:CLLS)

$32.43 -0.11 (-0.34 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$32.43
Today's Range$31.55 - $33.22
52-Week Range$19.76 - $35.07
Volume85,307 shs
Average Volume201,581 shs
Market Capitalization$1.14 billion
P/E Ratio-11.62
Dividend YieldN/A
BetaN/A

About Cellectis (NASDAQ:CLLS)

Cellectis logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CLLS
CUSIPN/A
Phone+33-1-81691600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.98%
Quick Ratio6.98%

Price-To-Earnings

Trailing P/E Ratio-11.6236559139785
Forward P/E Ratio-11.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$56.46 million
Price / Sales20.64
Cash FlowN/A
Price / CashN/A
Book Value$8.16 per share
Price / Book3.97

Profitability

Trailing EPS($2.79)
Net Income$-67,250,000.00
Net Margins-217.25%
Return on Equity-30.66%
Return on Assets-25.66%

Miscellaneous

Employees122
Outstanding Shares35,930,000

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) announced its earnings results on Monday, November, 16th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.03. The biotechnology company had revenue of $11.10 million for the quarter, compared to analyst estimates of $1.23 million. Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%. View Cellectis' Earnings History.

When will Cellectis make its next earnings announcement?

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Cellectis.

Where is Cellectis' stock going? Where will Cellectis' stock price be in 2018?

6 analysts have issued 12 month price targets for Cellectis' stock. Their forecasts range from $20.00 to $49.00. On average, they expect Cellectis' share price to reach $39.83 in the next year. View Analyst Ratings for Cellectis.

What are Wall Street analysts saying about Cellectis stock?

Here are some recent quotes from research analysts about Cellectis stock:

  • 1. According to Zacks Investment Research, "Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. " (2/14/2018)
  • 2. Instinet analysts commented, "Cellectis is a leader in gene-editing and autologous CAR-T therapy. Recently presented clinical data for UCART19 established proof-of-concept (POC) for a safe off-the-shelf CAR-T (UCART) therapy. We believe that this POC enables rapid development of novel UCART therapeutics and that next-generation treatment protocols and gene-edits entering clinical testing in 2017 will allow for next UCART therapies to enter trials in rapid succession, driving upside in the shares over the next 12 months. We also view the shares as attractively priced, given that CLLS, a clinical-stage biotech, trades at a discount to preclinical gene-editing and clinical-stage CAR-T peers." (3/1/2017)

Are investors shorting Cellectis?

Cellectis saw a decline in short interest in January. As of January 31st, there was short interest totalling 398,568 shares, a decline of 53.7% from the January 12th total of 860,402 shares. Based on an average daily trading volume, of 295,825 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.1% of the shares of the stock are short sold.

Who are some of Cellectis' key competitors?

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:

  • Andre Choulika, Chairman of the Board, Chief Executive Officer (Age 52)
  • Thierry Moulin, Chief Financial Officer
  • Mathieu Simon, Chief Operating Officer, Executive Vice President, Director
  • David J.D. Sourdive, Executive Vice President-Corporate Development, Director
  • Elsy Boglioli, Executive Vice President - Strategy and Corporate Development
  • Stephane Depil Ph.D. M.D., Senior Vice President - Research and Development and Chief Medical Officer
  • Philippe Duchateau, Chief Scientific Officer
  • Laurent Arthaud, Independent Director
  • Pierre Bastid, Independent Director
  • Alain Godard, Independent Director (Age 71)

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who owns Cellectis stock?

Cellectis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (0.97%), Sphera Funds Management LTD. (0.94%), BlackRock Inc. (0.42%), Lazard Asset Management LLC (0.42%), Millennium Management LLC (0.29%) and Bain Capital Public Equity Management LLC (0.27%). View Institutional Ownership Trends for Cellectis.

Who sold Cellectis stock? Who is selling Cellectis stock?

Cellectis' stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Sphera Funds Management LTD., Vident Investment Advisory LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Cellectis.

Who bought Cellectis stock? Who is buying Cellectis stock?

Cellectis' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Bain Capital Public Equity Management LLC, Millennium Management LLC, Granite Point Capital Management L.P., Hudson Bay Capital Management LP, ARK Investment Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Cellectis.

How do I buy Cellectis stock?

Shares of Cellectis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of Cellectis stock can currently be purchased for approximately $32.43.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.14 billion and generates $56.46 million in revenue each year. The biotechnology company earns $-67,250,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Cellectis employs 122 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 rue de la Croix Jarry, PARIS, 75013, France. The biotechnology company can be reached via phone at +33-1-81691600 or via email at [email protected]


MarketBeat Community Rating for Cellectis (CLLS)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellectis (NASDAQ:CLLS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.833.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $39.83$39.83$39.83$44.25
Price Target Upside: 39.13% upside39.13% upside19.80% upside75.66% upside

Cellectis (NASDAQ:CLLS) Consensus Price Target History

Price Target History for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ:CLLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/28/2017OppenheimerReiterated RatingOutperform$40.00 -> $40.00LowView Rating Details
10/29/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/6/2017SunTrust BanksReiterated RatingHold$20.00N/AView Rating Details
9/6/2017NomuraLower Price TargetBuy$49.00 -> $43.00LowView Rating Details
9/5/2017Wells Fargo & CoReiterated RatingOutperform -> Outperform$33.00 -> $40.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$49.00N/AView Rating Details
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00N/AView Rating Details
4/5/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$45.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Cellectis (NASDAQ:CLLS) Earnings History and Estimates Chart

Earnings by Quarter for Cellectis (NASDAQ:CLLS)

Cellectis (NASDAQ CLLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018        
11/13/2017Q3 2017($0.57)($0.73)$10.56 million$7.25 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.59)($0.74)$10.30 million$8.96 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.56)($0.56)$9.52 million$10.30 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.34)($0.38)$9.65 million$13.02 millionViewN/AView Earnings Details
11/22/2016Q3 2016($0.90)($0.40)$9.74 million$12.62 millionViewN/AView Earnings Details
9/8/2016Q2 2016($0.64)($0.20)$8.02 million$20.49 millionViewN/AView Earnings Details
5/11/2016Q1 2016($0.35)($0.92)$7.78 million$10.48 millionViewN/AView Earnings Details
3/14/2016Q4 2015($0.06)$0.25$5.72 million$31.97 millionViewN/AView Earnings Details
11/16/2015Q215($0.43)($0.40)$1.23 million$11.10 millionViewN/AView Earnings Details
9/8/2015Q2 2015($0.64)($0.70)$2.37 million$8.85 millionViewN/AView Earnings Details
6/9/2015Q1 2015$0.26$10.29 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cellectis (NASDAQ:CLLS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.89 EPS
Next Year EPS Consensus Estimate: $-2.62 EPS

Dividends

Dividend History for Cellectis (NASDAQ:CLLS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis (NASDAQ CLLS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Cellectis (NASDAQ CLLS) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 MillionZacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 Million
www.americanbankingnews.com - February 24 at 9:28 AM
Cellectis SA (CLLS) Receives Consensus Recommendation of "Buy" from BrokeragesCellectis SA (CLLS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 24 at 3:58 AM
 Analysts Expect Cellectis SA (CLLS) Will Post Earnings of -$0.64 Per Share Analysts Expect Cellectis SA (CLLS) Will Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - February 22 at 3:12 AM
BidaskClub Upgrades Cellectis (CLLS) to Strong-BuyBidaskClub Upgrades Cellectis (CLLS) to Strong-Buy
www.americanbankingnews.com - February 17 at 1:40 PM
Cellectis (CLLS) Downgraded by Zacks Investment Research to SellCellectis (CLLS) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - February 14 at 8:18 PM
Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)Financial Analysis: Cellectis (CLLS) vs. Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - February 13 at 9:12 PM
Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-CellsTwo Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells
finance.yahoo.com - February 13 at 9:44 AM
Cellectis SA (CLLS) Short Interest Down 53.7% in JanuaryCellectis SA (CLLS) Short Interest Down 53.7% in January
www.americanbankingnews.com - February 11 at 1:52 AM
 Brokerages Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 Million Brokerages Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $10.10 Million
www.americanbankingnews.com - February 7 at 6:56 AM
-$0.64 Earnings Per Share Expected for Cellectis SA (CLLS) This Quarter-$0.64 Earnings Per Share Expected for Cellectis SA (CLLS) This Quarter
www.americanbankingnews.com - February 5 at 3:12 AM
Cellectis SA (CLLS) Receives Average Recommendation of "Buy" from BrokeragesCellectis SA (CLLS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 30 at 3:46 AM
Prosensa (RNA) versus Cellectis (CLLS) Critical ReviewProsensa (RNA) versus Cellectis (CLLS) Critical Review
www.americanbankingnews.com - January 23 at 9:28 PM
Immunotherapy Stocks Power Higher on Celgene-Juno DealImmunotherapy Stocks Power Higher on Celgene-Juno Deal
www.thestreet.com - January 22 at 11:33 AM
$10.10 Million in Sales Expected for Cellectis SA (CLLS) This Quarter$10.10 Million in Sales Expected for Cellectis SA (CLLS) This Quarter
www.americanbankingnews.com - January 21 at 8:48 AM
-$0.64 EPS Expected for Cellectis SA (CLLS) This Quarter-$0.64 EPS Expected for Cellectis SA (CLLS) This Quarter
www.americanbankingnews.com - January 19 at 5:26 AM
Cellectis SA (CLLS) Sees Significant Increase in Short InterestCellectis SA (CLLS) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 14 at 2:32 AM
Cellectis SA (CLLS) Given Average Recommendation of "Buy" by BrokeragesCellectis SA (CLLS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 3:38 AM
Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PTCellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT
finance.yahoo.com - January 2 at 6:28 PM
Cellectis SA (CLLS) Expected to Post Earnings of -$0.64 Per ShareCellectis SA (CLLS) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - January 2 at 12:18 PM
Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City ... - 24/7 Wall St.Top Analyst Upgrades and Downgrades: Amex, Cellectis, ForeScout, Mastercard, Mueller Water, PG&E, Party City ... - 24/7 Wall St.
247wallst.com - December 28 at 3:50 PM
Cellectis (CLLS) Stock Rating Reaffirmed by OppenheimerCellectis (CLLS) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - December 28 at 11:52 AM
ETFs with exposure to Cellectis SA : December 26, 2017ETFs with exposure to Cellectis SA : December 26, 2017
finance.yahoo.com - December 28 at 9:02 AM
Cellectis SA :CLLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Cellectis SA :CLLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:59 PM
$10.66 Million in Sales Expected for Cellectis SA (CLLS) This Quarter$10.66 Million in Sales Expected for Cellectis SA (CLLS) This Quarter
www.americanbankingnews.com - December 18 at 10:22 AM
Cellectis SA (CLLS) Expected to Announce Earnings of -$0.67 Per ShareCellectis SA (CLLS) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - December 16 at 5:08 PM
Cellectis SA (CLLS) Is Sharply Higher On Study ResultsCellectis SA (CLLS) Is Sharply Higher On Study Results
www.nasdaq.com - December 13 at 9:59 AM
Cellectis SA (CLLS) Receives Consensus Recommendation of "Hold" from BrokeragesCellectis SA (CLLS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 3:38 AM
Stock Traders Buy High Volume of Call Options on Cellectis (CLLS)Stock Traders Buy High Volume of Call Options on Cellectis (CLLS)
www.americanbankingnews.com - December 9 at 2:38 AM
Critical Analysis: Cellectis (CLLS) and AC Immune (ACIU)Critical Analysis: Cellectis (CLLS) and AC Immune (ACIU)
www.americanbankingnews.com - December 6 at 9:10 PM
Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical OfficerCellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer
finance.yahoo.com - December 4 at 5:11 PM
Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate DevelopmentCellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development
finance.yahoo.com - December 4 at 5:11 PM
Cellectis (CLLS) Stock Rating Lowered by ValuEngineCellectis (CLLS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 7:16 PM
Analysts Issue Forecasts for Cellectis SAs Q4 2017 Earnings (CLLS)Analysts Issue Forecasts for Cellectis SA's Q4 2017 Earnings (CLLS)
www.americanbankingnews.com - November 30 at 11:02 AM
Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip FractureBlog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - November 30 at 10:07 AM
Cellectis SA (CLLS) Sees Large Decline in Short InterestCellectis SA (CLLS) Sees Large Decline in Short Interest
www.americanbankingnews.com - November 30 at 3:38 AM
Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive ImmunotherapyCellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy
finance.yahoo.com - November 20 at 6:21 PM
Cellectis (CLLS) Presents At Jefferies 2017 London Healthcare Conference - SlideshowCellectis (CLLS) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 5:00 PM
Zacks Investment Research Lowers Cellectis S.A. (CLLS) to HoldZacks Investment Research Lowers Cellectis S.A. (CLLS) to Hold
www.americanbankingnews.com - November 16 at 8:24 PM
ETFs with exposure to Cellectis SA : November 15, 2017ETFs with exposure to Cellectis SA : November 15, 2017
finance.yahoo.com - November 16 at 12:49 PM
Cellectis S.A. (CLLS) Receives Consensus Recommendation of "Buy" from AnalystsCellectis S.A. (CLLS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 16 at 3:58 AM
Cellectis (CLLS) CEO André Choulika on Q3 2017 Results - Earnings Call TranscriptCellectis' (CLLS) CEO André Choulika on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 5:18 AM
Cellectis SA to Host Earnings CallCellectis SA to Host Earnings Call
finance.yahoo.com - November 14 at 5:45 PM
Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017
finance.yahoo.com - November 13 at 10:40 PM
Short Interest in Cellectis S.A. (CLLS) Rises By 62.5%Short Interest in Cellectis S.A. (CLLS) Rises By 62.5%
www.americanbankingnews.com - November 13 at 2:32 AM
 Analysts Anticipate Cellectis S.A. (CLLS) to Post -$0.57 EPS Analysts Anticipate Cellectis S.A. (CLLS) to Post -$0.57 EPS
www.americanbankingnews.com - November 9 at 9:22 PM
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCNFDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN
finance.yahoo.com - November 6 at 11:31 PM
ETFs with exposure to Cellectis SA : November 3, 2017ETFs with exposure to Cellectis SA : November 3, 2017
finance.yahoo.com - November 4 at 7:27 AM
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual MeetingServier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 1 at 6:07 PM
Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual MeetingCellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting
finance.yahoo.com - November 1 at 6:07 PM
Calyxt Jumping Into A Crowded SpaceCalyxt Jumping Into A Crowded Space
seekingalpha.com - October 31 at 6:24 PM

SEC Filings

Cellectis (NASDAQ:CLLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellectis (NASDAQ:CLLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellectis (NASDAQ CLLS) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.